NASDAQ:EGRX - Eagle Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$41.49
▲ +0.2 (0.48%)
1 month | 3 months | 12 months
Get New Eagle Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EGRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EGRX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Eagle Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $41.49.

N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Eagle Pharmaceuticals. This rating has held steady since April 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/23/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/22/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/20/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/18/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/17/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/17/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/16/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/15/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/20/2020Cantor FitzgeraldReiterated RatingHold$46.00High
i
Rating by Brandon Folkes at Cantor Fitzgerald
3/25/2020Royal Bank of CanadaReiterated RatingBuy$59.00Medium
i
3/2/2020Cantor FitzgeraldLower Price TargetNeutral$58.00 ➝ $46.00High
i
8/11/2019Royal Bank of CanadaReiterated RatingBuy$66.00Low
i
Rating by Randall Stanicky at Royal Bank of Canada
5/7/2019Cantor FitzgeraldReiterated RatingHold$58.00Low
i
Rating by Brandon Folkes at Cantor Fitzgerald
4/24/2019MizuhoReiterated RatingHold$50.00Low
i
4/15/2019Cantor FitzgeraldReiterated RatingHold$58.00High
i
Rating by Brandon Folkes at Cantor Fitzgerald
3/22/2019MizuhoBoost Price TargetNeutral ➝ Neutral$40.00 ➝ $41.00High
i
3/1/2019Royal Bank of CanadaSet Price TargetBuy$66.00High
i
Rating by Randall Stanicky at Royal Bank of Canada
2/28/2019Cantor FitzgeraldReiterated RatingHold$58.00Medium
i
Rating by Brandon Folkes at Cantor Fitzgerald
11/7/2018MizuhoLower Price TargetNeutral$52.00Medium
i
11/2/2018Royal Bank of CanadaSet Price TargetBuy$64.00Medium
i
Rating by Randall Stanicky at Royal Bank of Canada
11/1/2018Cantor FitzgeraldDowngradeOverweight ➝ NeutralHigh
i
Rating by Brandon Folkes at Cantor Fitzgerald
10/31/2018Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$82.00 ➝ $54.00High
i
Rating by David Amsellem at Piper Jaffray Companies
10/30/2018Cantor FitzgeraldSet Price TargetBuy$80.00High
i
Rating by Brandon Folkes at Cantor Fitzgerald
10/3/2018Cantor FitzgeraldSet Price TargetBuy$80.00Low
i
Rating by Brandon Folkes at Cantor Fitzgerald
9/20/2018Cantor FitzgeraldLower Price TargetOverweight ➝ Buy$81.00 ➝ $80.00High
i
Rating by Brandon Folkes at Cantor Fitzgerald
8/24/2018Cantor FitzgeraldSet Price TargetBuy$81.00Low
i
Rating by Brandon Folkes at Cantor Fitzgerald
8/8/2018Royal Bank of CanadaSet Price TargetBuy$84.00Medium
i
Rating by Randall Stanicky at Royal Bank of Canada
8/7/2018Piper Jaffray CompaniesSet Price TargetBuy$88.00Low
i
Rating by David Amsellem at Piper Jaffray Companies
8/7/2018Cantor FitzgeraldSet Price TargetBuy$81.00Low
i
Rating by Brandon Folkes at Cantor Fitzgerald
7/24/2018Piper Jaffray CompaniesSet Price TargetBuy$86.00Low
i
Rating by David Amsellem at Piper Jaffray Companies
6/11/2018Cantor FitzgeraldInitiated CoverageOverweight$81.00High
i
6/11/2018MizuhoUpgradeUnderperform ➝ NeutralLow
i
5/17/2018MizuhoReiterated RatingUnderperform$54.00Low
i
5/10/2018MizuhoReiterated RatingSell$40.00Medium
i
3/21/2018MizuhoReiterated RatingUnderperform ➝ Underperform$37.00 ➝ $40.00Medium
i
2/26/2018Royal Bank of CanadaSet Price TargetBuy$71.00Medium
i
Rating by Randall Stanicky at Royal Bank of Canada
2/26/2018MizuhoReiterated RatingSell$37.00High
i
1/30/2018Piper Jaffray CompaniesReiterated RatingBuy$79.00Medium
i
Rating by David Amsellem at Piper Jaffray Companies
11/9/2017Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$81.00 ➝ $75.00N/A
i
Rating by Randall Stanicky at Royal Bank of Canada
11/8/2017MizuhoReiterated RatingSell$37.00N/A
i
10/27/2017Piper Jaffray CompaniesReiterated RatingBuy$75.00N/A
i
Rating by David Amsellem at Piper Jaffray Companies
9/6/2017MizuhoLower Price TargetUnderperform ➝ Underperform$40.00 ➝ $37.00High
i
8/9/2017Piper Jaffray CompaniesSet Price TargetBuy$75.00Medium
i
Rating by David Amsellem at Piper Jaffray Companies
7/27/2017Royal Bank of CanadaLower Price TargetOutperform ➝ Outperform$94.00 ➝ $81.00Medium
i
Rating by Randall Stanicky at Royal Bank of Canada
7/27/2017MizuhoLower Price TargetUnderperform ➝ Underperform$57.00 ➝ $40.00Medium
i
7/25/2017Piper Jaffray CompaniesSet Price TargetBuy$118.00Medium
i
Rating by David Amsellem at Piper Jaffray Companies
7/16/2017Royal Bank of CanadaSet Price TargetBuy$94.00Medium
i
Rating by Randall Stanicky at Royal Bank of Canada
5/25/2017MizuhoLower Price TargetUnderperform$66.00 ➝ $57.00Low
i
5/9/2017Piper Jaffray CompaniesSet Price TargetOverweight$90.00 ➝ $118.00High
i
5/9/2017Royal Bank of CanadaBoost Price TargetOutperform ➝ Outperform$86.00 ➝ $94.00High
i
Rating by Randall Stanicky at Royal Bank of Canada
4/24/2017Royal Bank of CanadaSet Price TargetBuy$86.00Medium
i
Rating by Randall Stanicky at Royal Bank of Canada
3/17/2017MizuhoReiterated RatingUnderperform$66.00High
i
3/2/2017Royal Bank of CanadaReiterated RatingOutperform$86.00N/A
i
2/27/2017MizuhoBoost Price TargetUnderperform$64.00 ➝ $66.00N/A
i
1/9/2017Royal Bank of CanadaReiterated RatingOutperform$93.00 ➝ $86.00N/A
i
1/9/2017MizuhoDowngradeNeutral ➝ Underperform$78.00 ➝ $64.00N/A
i
11/16/2016MizuhoDowngradeBuy ➝ Neutral$78.00N/A
i
Rating by Irina Rivkind Koffler at Mizuho
11/14/2016Royal Bank of CanadaReiterated RatingOutperform$93.00N/A
i
11/3/2016Royal Bank of CanadaReiterated RatingOutperform$80.00 ➝ $93.00N/A
i
11/3/2016Royal Bank of CanadaBoost Price TargetOutperform$80.00 ➝ $93.00N/A
i
Rating by Randall Stanicky at Royal Bank of Canada
11/3/2016MizuhoUpgradeNeutral ➝ Buy$62.00 ➝ $78.00N/A
i
Rating by Irina Rivkind Koffler at Mizuho
11/2/2016William BlairBoost Price TargetOutperform$83.00 ➝ $97.00N/A
i
10/26/2016MizuhoLower Price TargetBuy$65.00 ➝ $62.00N/A
i
Rating by Irina Rivkind Koffler at Mizuho
10/15/2016Piper Jaffray CompaniesReiterated RatingBuy$91.00N/A
i
Rating by David Amsellem at Piper Jaffray Companies
9/22/2016Royal Bank of CanadaReiterated RatingOutperform$78.00 ➝ $80.00N/A
i
8/16/2016MizuhoBoost Price TargetNeutral$47.00 ➝ $65.00N/A
i
Rating by Irina Rivkind Koffler at Mizuho
7/26/2016MizuhoReiterated RatingNeutral$37.80 ➝ $47.00N/A
i
Rating by Irina Rivkind Koffler at Mizuho
6/20/2016MizuhoDowngradeBuy ➝ Neutral$66.00 ➝ $47.00N/A
i
Rating by Irina Rivkind Koffler at Mizuho
(Data available from 6/16/2016 forward)
Eagle Pharmaceuticals logo
Eagle Pharmaceuticals, Inc., a biotechnology pharmaceutical company, focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also includes EP-4104, a dantrolene sodium for exertional heat stroke, as well as to treat organophosphate exposure; EP-5101 (PEMFEXY) for lung cancer and mesothelioma; EGL-5385-C-1701 (fulvestrant) for breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has a strategic collaboration with Tyme Technologies, Inc. to advance oral SM-88 for the treatment of patients with cancer. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Read More

Today's Range

Now: $41.49
$40.77
$41.68

50 Day Range

MA: $40.90
$36.86
$44.50

52 Week Range

Now: $41.49
$36.48
$53.43

Volume

94,350 shs

Average Volume

114,931 shs

Market Capitalization

$543.89 million

P/E Ratio

39.14

Dividend Yield

N/A

Beta

0.78

Frequently Asked Questions

What sell-side analysts currently cover shares of Eagle Pharmaceuticals?

The following equities research analysts have issued stock ratings on Eagle Pharmaceuticals in the last year: Zacks Investment Research.
View the latest analyst ratings for EGRX.

What is the current price target for Eagle Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Eagle Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Eagle Pharmaceuticals in the next year.
View the latest price targets for EGRX.

What is the current consensus analyst rating for Eagle Pharmaceuticals?

Eagle Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for EGRX.

What other companies compete with Eagle Pharmaceuticals?

How do I contact Eagle Pharmaceuticals' investor relations team?

Eagle Pharmaceuticals' physical mailing address is 50 TICE BOULEVARD SUITE 315, WOODCLIFF LAKE NJ, 07677. The specialty pharmaceutical company's listed phone number is 201-326-5300 and its investor relations email address is [email protected] The official website for Eagle Pharmaceuticals is www.eagleus.com.